RECRUITING

Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions

Conditions

Pancreatitis Pancreas Cancer Pancreas Cyst

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.

Official Title

The Role of Contrast Enhanced Endoscopic Ultrasound for Evaluation of Pancreas Lesions

Quick Facts

Study Start:2020-02-26

Study Completion:2025-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04324294

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients undergoing endoscopic ultrasound for pancreatic indications * Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings	* Patients \<18 years of age, pregnant women, and lactating mothers will be excluded. * Subjects with unstable cardiopulmonary condition will be excluded (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias) * Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts will be excluded given theoretical (though clinically insignificant) risk of embolization * Patients with a history of allergy to Lumason will be excluded

Inclusion Criteria

Exclusion Criteria

* Patients undergoing endoscopic ultrasound for pancreatic indications
* Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings

* Patients \<18 years of age, pregnant women, and lactating mothers will be excluded.
* Subjects with unstable cardiopulmonary condition will be excluded (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias)
* Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts will be excluded given theoretical (though clinically insignificant) risk of embolization
* Patients with a history of allergy to Lumason will be excluded

Contacts and Locations

Study Contact

Liliana Bancila

CONTACT

310 423 3872

liliana.bancila@cshs.org

Srinivas Gaddam, MD

CONTACT

310 423 6082

Srinivas.Gaddam@cshs.org

Principal Investigator

Srinivas Gaddam, MD

PRINCIPAL_INVESTIGATOR

Cedars-Sinai Medical Center

Study Locations (Sites)

Cedars-Sinai Medical Center

Los Angeles, California, 90048

United States

Collaborators and Investigators

Sponsor: Cedars-Sinai Medical Center

Srinivas Gaddam, MD, PRINCIPAL_INVESTIGATOR, Cedars-Sinai Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-02-26

Study Completion Date2025-12-31

Study Record Updates

Study Start Date2020-02-26

Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

Pancreatitis
Pancreas Cancer
Pancreas Cyst